Lehman & Derafelo Financial Resources LLC bought a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI) in the fourth quarter, HoldingsChannel reports. The fund bought 450 shares of the exchange traded fund’s stock, valued at approximately $32,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. JPMorgan Chase & Co. increased its holdings in SPDR S&P Biotech ETF by 98.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,265,715 shares of the exchange traded fund’s stock worth $313,084,000 after purchasing an additional 1,622,372 shares in the last quarter. Rafferty Asset Management LLC increased its stake in shares of SPDR S&P Biotech ETF by 114.1% in the third quarter. Rafferty Asset Management LLC now owns 941,464 shares of the exchange traded fund’s stock valued at $90,258,000 after buying an additional 501,695 shares during the period. Duality Advisers LP acquired a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter valued at about $51,363,000. First Republic Investment Management Inc. increased its stake in shares of SPDR S&P Biotech ETF by 1.6% in the third quarter. First Republic Investment Management Inc. now owns 523,329 shares of the exchange traded fund’s stock valued at $50,171,000 after buying an additional 8,257 shares during the period. Finally, LPL Financial LLC increased its stake in shares of SPDR S&P Biotech ETF by 19.9% in the third quarter. LPL Financial LLC now owns 343,810 shares of the exchange traded fund’s stock valued at $32,961,000 after buying an additional 57,179 shares during the period.

Shares of XBI stock opened at $91.27 on Friday. SPDR S&P Biotech ETF has a 1-year low of $64.38 and a 1-year high of $101.55.

TRADEMARK VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/lehman-derafelo-financial-resources-llc-buys-new-holdings-in-spdr-sp-biotech-etf-xbi/2895623.html.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Story: Why is the ROA ratio important?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.